These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 28595525)

  • 1. Obesity-Induced Hypertension: New Insights.
    Antza C; Stabouli S; Natsis M; Doundoulakis I; Kotsis V
    Curr Pharm Des; 2017; 23(31):4620-4625. PubMed ID: 28595525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formulary management of 2 new agents: lorcaserin and phentermine/topiramate for weight loss.
    Kelly EM; Tungol AA; Wesolowicz LA
    J Manag Care Pharm; 2013 Oct; 19(8):642-54. PubMed ID: 24074010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weight Loss Medications in the Treatment of Obesity and Hypertension.
    Cohen JB; Gadde KM
    Curr Hypertens Rep; 2019 Feb; 21(2):16. PubMed ID: 30747357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determining the Effects of Combined Liraglutide and Phentermine on Metabolic Parameters, Blood Pressure, and Heart Rate in Lean and Obese Male Mice.
    Simonds SE; Pryor JT; Koegler FH; Buch-Rasmussen AS; Kelly LE; Grove KL; Cowley MA
    Diabetes; 2019 Apr; 68(4):683-695. PubMed ID: 30674622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overview of new antiobesity drugs.
    Hainer V
    Expert Opin Pharmacother; 2014 Oct; 15(14):1975-8. PubMed ID: 25100293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current and emerging medications for overweight or obesity in people with comorbidities.
    Fujioka K
    Diabetes Obes Metab; 2015 Nov; 17(11):1021-32. PubMed ID: 26040215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New obesity agents: lorcaserin and phentermine/topiramate.
    Fleming JW; McClendon KS; Riche DM
    Ann Pharmacother; 2013; 47(7-8):1007-16. PubMed ID: 23800750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Obesity: The New Global Epidemic Pharmacological Treatment, Opportunities and Limits for Personalized Therapy.
    Milano W; De Biasio V; Di Munzio W; Foggia G; Capasso A
    Endocr Metab Immune Disord Drug Targets; 2020; 20(8):1232-1243. PubMed ID: 32410565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on obesity pharmacotherapy.
    Bray GA; Ryan DH
    Ann N Y Acad Sci; 2014 Apr; 1311():1-13. PubMed ID: 24641701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The pharmacotherapy of obesity].
    Budai KA; Mirzahosseini A; Noszál Béla ; Tóth G
    Acta Pharm Hung; 2015; 85(1):3-17. PubMed ID: 26137782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and tolerability of new-generation anti-obesity medications: a narrative review.
    Patel DK; Stanford FC
    Postgrad Med; 2018 Mar; 130(2):173-182. PubMed ID: 29388462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current and emerging pharmacotherapies for obesity in Australia.
    Hocking S; Dear A; Cowley MA
    Obes Res Clin Pract; 2017; 11(5):501-521. PubMed ID: 28818558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The new weight-loss drugs, lorcaserin and phentermine-topiramate: slim pickings?
    Woloshin S; Schwartz LM
    JAMA Intern Med; 2014 Apr; 174(4):615-9. PubMed ID: 24515599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Answers to Clinical Questions in the Primary Care Management of People with Obesity: Pharmacologic Management.
    Fujioka K; Braverman-Panza J
    J Fam Pract; 2016 Jul; 65(7 Suppl):S16-23. PubMed ID: 27565106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gender-related issues in the pharmacology of new anti-obesity drugs.
    Cataldi M; Muscogiuri G; Savastano S; Barrea L; Guida B; Taglialatela M; Colao A
    Obes Rev; 2019 Mar; 20(3):375-384. PubMed ID: 30589980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacologic Approaches to Weight Management: Recent Gains and Shortfalls in Combating Obesity.
    Saunders KH; Kumar RB; Igel LI; Aronne LJ
    Curr Atheroscler Rep; 2016 Jul; 18(7):36. PubMed ID: 27181165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Past and present of antiobesity agents: focus on monoamine modulators.
    Khorassani FE; Misher A; Garris S
    Am J Health Syst Pharm; 2015 May; 72(9):697-706. PubMed ID: 25873617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistence of newer anti-obesity medications in a real-world setting.
    Ganguly R; Tian Y; Kong SX; Hersloev M; Hobbs T; Smolarz BG; Ramasamy A; Haase CL; Weng W
    Diabetes Res Clin Pract; 2018 Sep; 143():348-356. PubMed ID: 30009937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.
    Gadde KM; Allison DB; Ryan DH; Peterson CA; Troupin B; Schwiers ML; Day WW
    Lancet; 2011 Apr; 377(9774):1341-52. PubMed ID: 21481449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity.
    Hendricks EJ; Greenway FL; Westman EC; Gupta AK
    Obesity (Silver Spring); 2011 Dec; 19(12):2351-60. PubMed ID: 21527891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.